OPKO Health, Inc. Finance Lease, Principal Payments
OPKO Health, Inc. (OPK) reported Finance Lease, Principal Payments of $821.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-28
- OPKO Health, Inc. finance lease, principal payments for the quarter ending 2026-06-30 was $370.00K, a 9.47% increase year-over-year.
- OPKO Health, Inc. finance lease, principal payments for the quarter ending 2026-03-31 was $451.00K, a 97.81% increase year-over-year.
- OPKO Health, Inc. finance lease, principal payments for the quarter ending 2025-12-31 was $709.00K, a 70.43% increase year-over-year.
- OPKO Health, Inc. finance lease, principal payments for the quarter ending 2025-09-30 was $205.00K, a 75.88% decline year-over-year.
- OPKO Health, Inc. finance lease, principal payments for fiscal 2025 was $1.48M, a 41.59% decline from fiscal 2024.
- OPKO Health, Inc. finance lease, principal payments for fiscal 2024 was $2.53M, a 14.45% increase from fiscal 2023.
- OPKO Health, Inc. finance lease, principal payments for fiscal 2023 was $2.21M, a 66.22% increase from fiscal 2022.
- OPKO Health, Inc. finance lease, principal payments for fiscal 2022 was $1.33M, a 33.70% decline from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $370.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $821.00K 10-Q/A · filed 2026-08-28 | $1.53M derived: sum of 3 quarters · filed 2026-08-28 | $1.74M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $451.00K 10-Q/A · filed 2026-08-28 | $1.16M derived: sum of 2 quarters · filed 2026-08-28 | $1.36M derived: sum of 3 quarters · filed 2026-08-28 | $1.70M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $914.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.25M derived: sum of 3 quarters · filed 2026-08-28 | $1.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $205.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $543.00K derived: sum of 2 quarters · filed 2026-08-28 | $771.00K 10-Q · filed 2025-10-29 | $1.19M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $338.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $566.00K 10-Q/A · filed 2026-08-28 | $982.00K derived: sum of 3 quarters · filed 2026-08-28 | $1.83M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $228.00K 10-Q/A · filed 2026-08-28 | $644.00K derived: sum of 2 quarters · filed 2026-08-28 | $1.49M derived: sum of 3 quarters · filed 2026-08-28 | $2.12M derived: sum of 4 quarters · filed 2026-08-28 |
| 2024-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.27M derived: sum of 2 quarters · filed 2026-02-26 | $1.89M derived: sum of 3 quarters · filed 2026-02-26 | $2.53M 10-K · filed 2026-02-26 |
| 2024-09-30 | $850.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.48M derived: sum of 2 quarters · filed 2025-10-29 | $2.12M 10-Q · filed 2025-10-29 | $2.41M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.27M 10-Q · filed 2025-07-31 | $1.56M derived: sum of 3 quarters · filed 2025-07-31 | $2.21M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $640.00K 10-Q · filed 2025-05-01 | $935.00K derived: sum of 2 quarters · filed 2025-05-01 | $1.59M derived: sum of 3 quarters · filed 2025-05-01 | $2.20M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $946.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.56M derived: sum of 3 quarters · filed 2025-03-03 | $2.21M 10-K · filed 2025-03-03 |
| 2023-09-30 | $651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.26M derived: sum of 2 quarters · filed 2024-11-07 | $1.92M 10-Q · filed 2024-11-07 | $2.23M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $612.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.27M 10-Q · filed 2024-08-07 | $1.58M derived: sum of 3 quarters · filed 2024-08-07 | $1.88M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $656.00K 10-Q · filed 2024-05-07 | $968.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.26M derived: sum of 3 quarters · filed 2024-05-07 | $1.49M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $608.00K derived: sum of 2 quarters · filed 2024-03-01 | $834.00K derived: sum of 3 quarters · filed 2024-03-01 | $1.33M 10-K · filed 2024-03-01 |
| 2022-09-30 | $296.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $522.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.02M 10-Q · filed 2023-11-06 | $1.53M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $724.00K 10-Q · filed 2023-08-03 | $1.24M derived: sum of 3 quarters · filed 2023-08-03 | $1.96M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $498.00K 10-Q · filed 2023-05-03 | $1.01M derived: sum of 2 quarters · filed 2023-05-03 | $1.74M derived: sum of 3 quarters · filed 2023-05-03 | $1.98M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.24M derived: sum of 2 quarters · filed 2023-02-27 | $1.48M derived: sum of 3 quarters · filed 2023-02-27 | $2.01M 10-K · filed 2023-02-27 |
| 2021-09-30 | $729.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $973.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.50M 10-Q · filed 2022-11-08 | $2.36M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $244.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $769.00K 10-Q · filed 2022-08-04 | $1.63M derived: sum of 3 quarters · filed 2022-08-04 | $2.62M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $525.00K 10-Q · filed 2022-05-09 | $1.39M derived: sum of 2 quarters · filed 2022-05-09 | $2.37M derived: sum of 3 quarters · filed 2022-05-09 | $2.90M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.85M derived: sum of 2 quarters · filed 2022-03-01 | $2.38M derived: sum of 3 quarters · filed 2022-03-01 | $2.87M 10-K · filed 2022-03-01 |
| 2020-09-30 | $983.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $1.52M derived: sum of 2 quarters · filed 2021-10-28 | $2.01M 10-Q · filed 2021-10-28 | $2.68M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $533.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $1.03M 10-Q · filed 2021-07-29 | $1.69M derived: sum of 3 quarters · filed 2021-07-29 | $2.27M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $493.00K 10-Q · filed 2021-04-28 | $1.16M derived: sum of 2 quarters · filed 2021-04-28 | $1.74M derived: sum of 3 quarters · filed 2021-04-28 | $2.67M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $1.24M derived: sum of 2 quarters · filed 2021-02-18 | $2.17M derived: sum of 3 quarters · filed 2021-02-18 | $2.83M 10-K · filed 2021-02-18 |
| 2019-09-30 | $575.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.50M derived: sum of 2 quarters · filed 2020-10-29 | $2.17M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $930.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.59M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $660.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |